GB2157171B - Pharmaceutical compositions having cerebral antianoxic and metabolic activities - Google Patents

Pharmaceutical compositions having cerebral antianoxic and metabolic activities

Info

Publication number
GB2157171B
GB2157171B GB08508452A GB8508452A GB2157171B GB 2157171 B GB2157171 B GB 2157171B GB 08508452 A GB08508452 A GB 08508452A GB 8508452 A GB8508452 A GB 8508452A GB 2157171 B GB2157171 B GB 2157171B
Authority
GB
United Kingdom
Prior art keywords
antianoxic
cerebral
pharmaceutical compositions
metabolic activities
metabolic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB08508452A
Other languages
English (en)
Other versions
GB8508452D0 (en
GB2157171A (en
Inventor
Alberto Bertelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seuref AG
Original Assignee
Seuref AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seuref AG filed Critical Seuref AG
Publication of GB8508452D0 publication Critical patent/GB8508452D0/en
Publication of GB2157171A publication Critical patent/GB2157171A/en
Application granted granted Critical
Publication of GB2157171B publication Critical patent/GB2157171B/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GB08508452A 1984-04-09 1985-04-01 Pharmaceutical compositions having cerebral antianoxic and metabolic activities Expired GB2157171B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH1774/84A CH661438A5 (it) 1984-04-09 1984-04-09 Composizioni farmaceutiche ad azione antianossica e metabolica cerebrale.

Publications (3)

Publication Number Publication Date
GB8508452D0 GB8508452D0 (en) 1985-05-09
GB2157171A GB2157171A (en) 1985-10-23
GB2157171B true GB2157171B (en) 1988-07-06

Family

ID=4218293

Family Applications (1)

Application Number Title Priority Date Filing Date
GB08508452A Expired GB2157171B (en) 1984-04-09 1985-04-01 Pharmaceutical compositions having cerebral antianoxic and metabolic activities

Country Status (7)

Country Link
US (1) US4684520A (enExample)
JP (1) JPS6133118A (enExample)
CH (1) CH661438A5 (enExample)
DE (1) DE3417857C2 (enExample)
FR (1) FR2562422B1 (enExample)
GB (1) GB2157171B (enExample)
IT (1) IT1201412B (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH661443A5 (en) * 1984-11-22 1987-07-31 Seuref Ag Pharmaceutical compositions having metabolic activity
JPH01305032A (ja) * 1988-06-01 1989-12-08 Sanwa Kagaku Kenkyusho Co Ltd 機能後退性消耗疾患治療予防剤及び飲食、し好物
JPH01305033A (ja) * 1988-06-01 1989-12-08 Sanwa Kagaku Kenkyusho Co Ltd 循環改善剤及び循環改善機能性食品並びにし好品
JPH02188523A (ja) * 1989-01-13 1990-07-24 M S C:Kk 睡眠時無呼吸症治療薬
US6461593B1 (en) * 1992-02-19 2002-10-08 Biomedical And Clinical Research Therapy with coenzyme Q10 to reduce subgingival microorganisms in patients with periodontal disease
WO1994015595A1 (en) * 1993-01-06 1994-07-21 Jemo-Pharm A/S Medium comprising a pharmacological/biological active substance
US6312703B1 (en) 1998-02-06 2001-11-06 Lecigel, Llc Compressed lecithin preparations
US20030040505A1 (en) * 2000-03-31 2003-02-27 The Regents Of The University Of California Synthetic phospholipids to ameliorate atherosclerosis and other inflammatory conditions
US7144862B2 (en) * 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US6441050B1 (en) * 2000-08-29 2002-08-27 Raj K. Chopra Palatable oral coenzyme Q liquid
KR100612398B1 (ko) * 2000-11-14 2006-08-16 바이탈 헬스 사이언시즈 피티와이 리미티드 포스페이트 유도체의 착체
AUPR549901A0 (en) * 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
AU2002317053B2 (en) * 2001-07-27 2004-08-05 Vital Health Sciences Pty Ltd Dermal therapy using phosphate derivatives of electron transfer agents
AUPR684801A0 (en) * 2001-08-06 2001-08-30 Vital Health Sciences Pty Ltd Supplement therapy
BR0215102A (pt) * 2001-12-13 2004-11-03 Vital Health Sciences Pty Ltd Transporte transdermal de compostos, formulação tópica, método para melhorar a absorção da pele, método para a terapia de reposição hormonal, uso de um ou mais derivados de fosfato de um composto hidróxi farmacêutico em um sistema de aplicação transdermal, sistema de aplicação transdermal, método para aplicação de um composto hidróxi farmacêutico a um indivìduo e para melhorar a eficácia de uma formulação
JP2003261456A (ja) * 2002-03-08 2003-09-16 Howaizu:Kk 脳の老化予防剤
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
BRPI0406484A (pt) * 2003-01-17 2005-12-06 Vital Health Sciences Pty Ltd Método de inibição da ocorrência de uma ou mais das seguintes condições: a proliferação de monócitos/macrófagos; ou a proliferação de células do músculo liso; ou a expressão de receptores de cd36; ou a absorção de lipoproteìna de baixa densidade - ldl oxidada, método de alìvio de sintomas de tratamento ou prevenção de aterosclerose; de diabetes; do mal de alzheimer, método de inibição da ocorrência da formação de placas no sistema vascular, método de alìvio da inflamação associada a ocorrência de uma ou de mais das seguintes condições: a proliferação de monócitos, a proliferação de células do músculo liso, a expressão de ldl oxidadas ou de receptor descontaminante, composição farmacêutica, uso de uma quantidade eficaz de um ou mais derivados ou fosfato de um ou mais agentes de transferência de elétrons conjuntamente com um veìculo ou um diluente apropriado, uso de uma quantidade eficaz de um ou mais derivados de fosfato de (alfa)-tocoferol conjuntamente com um veìculo ou um diluente apropriado e uso de uma quantidade eficaz de um ou mais derivados de fosfato de um ou mais agentes de transferência de elétrons selecionados do grupo que consiste em fosfato mono-tocoferila, fosfato de di-tocoferila e as misturas destes conjuntamente com um veìculo ou um diluente apropriado
AU2003901815A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
US8252322B2 (en) * 2003-06-03 2012-08-28 Corn Products Development, Inc. Delivery system with increased bioavailability
TW200524541A (en) * 2003-11-17 2005-08-01 Cargill Inc Lecithin-containing granular compositions and methods of their preparation
US20060069157A1 (en) * 2004-02-19 2006-03-30 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as Huntington's disease, by sodium butyrate chemotherapy
CA2557354C (en) 2004-03-03 2013-05-07 Vital Health Sciences Pty Ltd. Alkaloid formulations
RU2448977C2 (ru) * 2004-09-16 2012-04-27 Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье Обладающий способностью облегчать по меньшей мере один симптом воспалительного состояния пептид, содержащая его фармацевтическая композиция и способ лечения атеросклероза с их помощью
US7901675B2 (en) * 2004-10-13 2011-03-08 U.S. Department Of Veterans Affairs Method of using coenzyme Q10 to treat Huntington's disease
US7579319B2 (en) 2004-12-06 2009-08-25 The Regents Of The University Of California Methods for improving the structure and function of arterioles
US20060135612A1 (en) * 2004-12-17 2006-06-22 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
WO2006092024A1 (en) * 2005-03-03 2006-09-08 Vital Health Sciences Pty Ltd Compounds having anti-cancer properties
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
EP1890715A4 (en) * 2005-04-29 2009-10-28 Univ California PEPTIDES AND PEPTIDE MIMETICS FOR TREATMENT BY INFLAMMATORY REACTION OF CHARACTERIZED PATHOLOGIES
MX2007015949A (es) * 2005-06-17 2008-03-07 Vital Health Sciences Pty Ltd Un vehiculo que comprende uno o mas derivados de fosfato de di- y/o mono-(agentes de transferencia de electrones) o complejos de los mismos.
DE102005056558B4 (de) * 2005-11-25 2009-04-30 Gisela Susilo Kombinationspräparate enthaltend physiologische Zellmembran-Bestandteile
WO2007070981A1 (en) * 2005-12-23 2007-06-28 Vital Health Sciences Pty Ltd Compounds having cytokine modulating properties
GB0603975D0 (en) * 2006-03-01 2006-04-05 Etren Methods and agents for reducing oxidative stress
CA2649315A1 (en) * 2006-04-10 2007-10-25 Mitsubishi Gas Chemical Company, Inc. Brain function-improving agent, and functional food containing the improving agent
US20100061969A1 (en) * 2006-11-22 2010-03-11 Asahi Kasei Pharma Corporation Dietary supplement, anti-fatigue agent or physical endurance enhancer, functional food, or cosmetic
EP2195331B1 (en) 2007-08-28 2013-11-20 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
US10071030B2 (en) 2010-02-05 2018-09-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
JP5806287B2 (ja) 2010-03-30 2015-11-10 フォスファジェニクス リミティド 経皮送達パッチ
WO2012122586A1 (en) 2011-03-15 2012-09-20 Phosphagenics Limited New composition
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose
CA2954475C (en) 2014-07-31 2023-05-16 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
MX383940B (es) 2015-12-09 2025-03-14 Phosphagenics Ltd Formulación farmacéutica que contiene tocol fosfato.
JP7198754B2 (ja) 2016-12-21 2023-01-04 アベーチョ バイオテクノロジー リミテッド 方法
US12264593B1 (en) 2023-11-09 2025-04-01 Pratt & Whitney Canada Corp. Damped bladed rotor for gas turbine engine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5938202B2 (ja) * 1976-03-05 1984-09-14 エーザイ株式会社 難聴治療剤
JPS5356315A (en) * 1976-11-01 1978-05-22 Eisai Co Ltd Emulsified solution of fat soluble drugs
US4221784A (en) * 1979-04-05 1980-09-09 Massachusetts Institute Of Technology Process and composition for treating disorders by administering lecithin
FR2472384A1 (fr) * 1979-12-27 1981-07-03 Sederma Sa Utilisation en cosmetologie de complexes naturels constitues d'ubiquinones et de phospholipides
JPS5742616A (en) * 1980-08-27 1982-03-10 Furointo Sangyo Kk Ubiquinone pharmaceutical having improved absorption
JPS5775916A (en) * 1980-10-29 1982-05-12 Nippon Chemiphar Co Ltd Coenzyme q pharmaceutical and its preparation
JPS57142911A (en) * 1981-02-28 1982-09-03 Furointo Sangyo Kk Absorption-improving agent
JPS58113127A (ja) * 1981-12-28 1983-07-05 Ajinomoto Co Inc ユビデカレノン含有水性液
CH649917A5 (en) * 1982-03-19 1985-06-28 Italfarmaco Sa Pharmaceutical formulations containing the coenzyme Q(10) suitable for topical administration
JPS58201711A (ja) * 1982-05-19 1983-11-24 Eisai Co Ltd ユビデカレノン含有リポソ−ム被覆体

Also Published As

Publication number Publication date
GB8508452D0 (en) 1985-05-09
FR2562422B1 (fr) 1989-03-31
JPH0530813B2 (enExample) 1993-05-11
JPS6133118A (ja) 1986-02-17
IT1201412B (it) 1989-02-02
DE3417857C2 (de) 1997-04-24
DE3417857A1 (de) 1985-10-17
US4684520A (en) 1987-08-04
GB2157171A (en) 1985-10-23
CH661438A5 (it) 1987-07-31
FR2562422A1 (fr) 1985-10-11
IT8520271A0 (it) 1985-04-05

Similar Documents

Publication Publication Date Title
NZ211145A (en) 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
NZ212005A (en) Pyrrolobenzimidazoles and pharmaceutical compositions
IL74758A (en) Acyltripeptides and pharmaceutical compositions containing them
NZ212099A (en) Substituted arylhydroxamates and pharmaceutical compositions
NZ213812A (en) Sulphonamides and pharmaceutical compositions
GB2153678B (en) Pharmaceutical composition
EP0173990A3 (en) External pharmaceutical composition
IT1201412B (it) Composizioni farmaceutiche ad azione antianossica e metabolica cerebrale
NZ216918A (en) Pyridazines and pharmaceutical compositions
EP0163178A3 (en) Pharmaceutical composition
NZ211031A (en) 6-substituted-4-dialkylaminotetrahindole derivatives and pharmaceutical compositions
IL74865A (en) 4'-amino-9a-aza-9a-homoerythromycin derivatives and pharmaceutical compositions containing them
NZ212499A (en) Substituted benzamide derivatives and pharmaceutical compositions
NZ211905A (en) Phenol derivatives having antioestrogenic activity and pharmaceutical compositions
GB2153677B (en) Pharmaceutical composition
NZ209095A (en) Piperidinoquinazolines and pharmaceutical compositions
NZ210818A (en) 8-alpha-acylaminoergoline derivatives and pharmaceutical compositions
NZ212953A (en) 3-acyl-1-aminoalkyl-1h-indoles and pharmaceutical compositions thereof
NZ214088A (en) 1,3-diazoles and pharmaceutical compositions
NZ208244A (en) Phenyl-pyrazol-3-ones and pharmaceutical compositions
NZ213581A (en) Carboxyalkyldipeptides and pharmaceutical compositions
NZ214048A (en) Cephalosporins and pharmaceutical compositions
NZ214284A (en) Benzamide derivatives and pharmaceutical compositions
PH21779A (en) Sulfonomidines and pharmaceutical compositions containing the same
IL74667A (en) Spiro-oxazolidones,-thiazolidones and-imidazolidones and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)
PE20 Patent expired after termination of 20 years

Effective date: 20050331